| Outcome Measures: |
Primary: HbA1c, The primary outcome of this study is to assess changes in HbA1c in both treatment arms, 26 weeks | Secondary: HbA1c < 7.0%, Percentages of subjects achieving HbA1c \< 7.0% is measured in both treatment arms, 26 weeks|HbA1c ≤ 6.5%, Percentages of subjects achieving HbA1c ≤ 6.5% is measured in both treatment arms, 26 weeks|Body weight, Changes in body weight is measured in both treatment arms, 26 weeks|Fasting blood sugar, Changes in FBS is measured in both treatment arms, 26 weeks|Postprandial glucose, Changes in mean PPG is measured in both treatment arms, 26 weeks|Systolic blood pressure, Changes in SBP (mmHg) is measured in both treatment arms, 26 weeks|Diastolic blood pressure, Changes in DBP (mmHg) is measured in both treatment arms, 26 weeks|Lipid profiles, Changes in Lipid profiles is measured in both treatment arms, 26 weeks|Pulse Rate, Changes in PR is measured in both treatment arms, 26 weeks|estimated Glomerular Filtration Rate, Changes in eGFR is measured in both treatment arms, 26 weeks|Liver enzymes, Changes in AST and ALT is measured in both treatment arms, 26 weeks
|
